Company No:
Contents
DIRECTORS | Gemma Butcher |
Joseph Butcher | |
Bethany Lampl | |
William Narey |
REGISTERED OFFICE | Unit 7c A30 Business Park |
Indian Queens | |
Newquay | |
England | |
TR9 6FZ | |
United Kingdom |
COMPANY NUMBER | 11903551 (England and Wales) |
CHARTERED ACCOUNTANTS | Francis Clark LLP |
Lowin House | |
Tregolls Road | |
Truro | |
Cornwall TR1 2NA |
Note | 30.09.2023 | 30.09.2022 | ||
£ | £ | |||
Fixed assets | ||||
Intangible assets | 3 |
|
|
|
Tangible assets | 4 |
|
|
|
420,408 | 230,301 | |||
Current assets | ||||
Stocks |
|
|
||
Debtors | 5 |
|
|
|
Cash at bank and in hand |
|
|
||
702,247 | 614,987 | |||
Creditors: amounts falling due within one year | 6 | (
|
(
|
|
Net current assets | 330,067 | 353,026 | ||
Total assets less current liabilities | 750,475 | 583,327 | ||
Creditors: amounts falling due after more than one year | 7 | (
|
(
|
|
Net liabilities | (
|
(
|
||
Capital and reserves | ||||
Called-up share capital | 8 |
|
|
|
Profit and loss account | (
|
(
|
||
Total shareholders' deficit | (
|
(
|
Directors' responsibilities:
The financial statements of Certus Biomedical Limited (registered number:
Joseph Butcher
Director |
The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial period, unless otherwise stated.
Certus Biomedical Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is Unit 7c A30 Business Park, Indian Queens, Newquay, England, TR9 6FZ, United Kingdom.
The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.
The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.
The directors have assessed the Balance Sheet and likely future cash flows at the date of approving these financial statements. The directors note that the business has net liabilities of £213,772. The Company is supported through loans from the Parent Company. The directors have received assurances that the loan facilities will continue to be available for at least 12 months from the date of signing these financial statements and the Parent Company will continue to support the Company. After making enquiries, the directors believe that any foreseeable debts can be met for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.
The company recognises revenue when the amount of revenue can be reliably measured, it is probable that future economic benefits will flow to the entity and specific criteria have been met for each of the company's activities.
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.
Other intangible assets |
|
Leasehold improvements | not depreciated |
Plant and machinery |
|
Vehicles |
|
Fixtures and fittings |
|
Computer equipment |
|
Assets held under finance leases, hire purchase contracts and other similar arrangements, which confer rights and obligations similar to those attached to owned assets, are capitalised as tangible fixed assets at the fair value of the leased asset (or, if lower, the present value of the minimum lease payments as determined at the inception of the lease) and are depreciated over the shorter of the lease terms and their useful lives. The capital elements of future lease obligations are recorded as liabilities, while the interest elements are charged to the Statement of Income and Retained Earnings over the period of the leases to produce a constant periodic rate of interest on the remaining balance of the liability.
Rentals under operating leases are charged on a straight-line basis over the lease term, even if the payments are not made on such a basis. Benefits received and receivable as an incentive to sign an operating lease are similarly spread on a straight-line basis over the lease term.
Assets, other than those measured at fair value, are assessed for indicators of impairment at each Balance Sheet date. If there is objective evidence of impairment, an impairment loss is recognised in the Statement of Income and Retained Earnings as described below.
Year ended 30.09.2023 |
Period from 01.04.2021 to 30.09.2022 |
||
Number | Number | ||
Monthly average number of persons employed by the Company during the year, including directors |
|
|
Other intangible assets | Total | ||
£ | £ | ||
Cost | |||
At 01 October 2022 |
|
|
|
Additions |
|
|
|
At 30 September 2023 |
|
|
|
Accumulated amortisation | |||
At 01 October 2022 |
|
|
|
Charge for the financial year |
|
|
|
At 30 September 2023 |
|
|
|
Net book value | |||
At 30 September 2023 |
|
|
|
At 30 September 2022 |
|
|
Leasehold improve- ments |
Plant and machinery | Vehicles | Fixtures and fittings | Computer equipment | Total | ||||||
£ | £ | £ | £ | £ | £ | ||||||
Cost | |||||||||||
At 01 October 2022 |
|
|
|
|
|
|
|||||
Additions |
|
|
|
|
|
|
|||||
Disposals |
|
|
(
|
|
|
(
|
|||||
At 30 September 2023 |
|
|
|
|
|
|
|||||
Accumulated depreciation | |||||||||||
At 01 October 2022 |
|
|
|
|
|
|
|||||
Charge for the financial year |
|
|
|
|
|
|
|||||
Disposals |
|
|
(
|
|
|
(
|
|||||
At 30 September 2023 |
|
|
|
|
|
|
|||||
Net book value | |||||||||||
At 30 September 2023 |
|
|
|
|
|
|
|||||
At 30 September 2022 |
|
|
|
|
|
|
30.09.2023 | 30.09.2022 | ||
£ | £ | ||
Trade debtors |
|
|
|
Other debtors |
|
|
|
|
|
30.09.2023 | 30.09.2022 | ||
£ | £ | ||
Trade creditors |
|
|
|
Other taxation and social security |
|
|
|
Obligations under finance leases and hire purchase contracts |
|
|
|
Other creditors |
|
|
|
|
|
30.09.2023 | 30.09.2022 | ||
£ | £ | ||
Obligations under finance leases and hire purchase contracts |
|
|
|
Other creditors |
|
|
|
|
|
30.09.2023 | 30.09.2022 | ||
£ | £ | ||
Allotted, called-up and fully-paid | |||
|
|
|
Transactions with the entity's directors
30.09.2023 | 30.09.2022 | ||
£ | £ | ||
Director's Loan Accounts - J & G Butcher | 64,008 | 12,885 | |
Director's Loan Accounts - W Narey | (135,061) | (61,672) |
The total amount of £71,053 is due by the Company to the Directors (£48,787 in 2022).
Advances
Other related party transactions
30.09.2023 | 30.09.2022 | ||
£ | £ | ||
Global Inhalation Equipment Limited | 616,009 | 727,957 | |
Hypneuma Limited | 33,358 | 53,390 |
Included in creditors due less than one year are amounts due to Hypneuma Limited (£33,358). Included within creditors due more than one year is an amount due to Global Inhalation Equipment Limited (£616,009).
Global Inhalation Equipment Limited is the parent company of Certus Biomedical Limited. It also has significant control of Hypneuma Limited.